Loading...
•
Dec 31, 2023
Pacific Biosciences Q4 2023 Earnings Report
Pacific Biosciences announced results for Q4 2023, with increased revenue and progress in install base and sequencing efficiency.
Key Takeaways
Pacific Biosciences reported Q4 2023 revenue of $73.2 million, exceeding expectations and representing a 95% increase year-over-year. The company saw growth in instrument revenue and consumables revenue. Continued progress was made on increasing the installed base of Revio systems and improving sequencing economics.
Q4 revenue reached $73.2 million, a 95% increase compared to Q4 2022.
Instrument revenue was $37.1 million, driven by Revio sales.
Consumables revenue totaled $29.1 million, reflecting increased Sequel II/IIe utilization and initial Revio utilization.
PacBio added 47 Revio systems to its installed base during the quarter, bringing the total to 192.
Revenue by Segment
Forward Guidance
PacBio anticipates revenue for full year 2024 to be in the range of $170 million to $200 million.
Positive Outlook
- Continued expansion of the Revio installed base.
- Increased utilization of Revio and Sequel II/IIe systems.
- Growth in sequencing consumables revenue.
- Potential for new product launches and technology advancements.
- Expanding market opportunities in clinical and applied markets.
Challenges Ahead
- Uncertainties in the macroeconomic environment could affect customer spending.
- Competition from other sequencing technology providers.
- Potential delays in product development or regulatory approvals.
- Risks associated with managing a growing installed base and supply chain.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...